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Fig 1. Dermatomyositis. Erythematous papules overlying
the metacarpal and interphalangeal joints (Gottron
papules).
Fig 2. Dermatomyositis. Hematoxylin and eosin stain of
dorsal hand punch biopsy. Vacuolar interface dermatitis
with sparse perivascular inflammation.
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Dermatomyositis associated with antietumor
necrosis factor therapy in a patient with
psoriasis
To the Editor: Antietumor necrosis factor (a-TNF)
agents have become a common treatment for many
different autoimmune diseases. Due to conflicting
effects mediated by TNF, a-TNF therapies both
treat and induce autoimmune disease. Herein we
discuss a novel case of a-TNFeinduced amyopathic
dermatomyositis (DM) in a patient with a history of
psoriasis.
A 37-year-old Brazilian woman was referred to
our medical center for management of psoriasis. She
had a 7-year history of biopsy-proven psoriatic
plaques that had failed topical therapies and were
exacerbated by UV therapy. Physical exam revealed
a large 20- 3 30-cm erythematous, scaly plaque on
her back, and more than 20 guttate papules on her
elbows and extensor forearms. She was started on
adalimumab 40 mg biweekly following routine lab
work and a negative tuberculosis test.
One month later, her psoriasiform plaques
had markedly improved, but indurated violaceous
plaques overlying her knuckles with ragged cuticles
and looped telangiectasias developed (Fig 1).
Because she was satisfied with the resolving
psoriasis, adalimumab was continued.
Open access under CC BY-NC-ND license.A biopsy specimen from the periarticular dorsal
hand skin papule was obtained (Fig 2).
Biopsy revealed an atrophic epidermis and subtle
vacuolar interface change associated with sparse
superficial perivascular inflammation with increased
dermal mucin. She denied myalgias or muscle
weakness. Laboratory findings revealed a negative
ANA, negative SCL70, a creatine kinase of 136 U/L,
and a jo-1 \ 1. Based on the clinical, laboratory,
and pathologic findings, the diagnosis of DM
was made. The patient has had negative results
on age-appropriate cancer screenings, including
gynecologic exam, computed tomography of
abdomen/pelvis, and chest roentgenogram, as well
as normal pulmonary function tests. Over the
subsequent 10 months, she has had no other
manifestations of DM. Her Gottron papules have
softened somewhat with the addition of metho-
trexate. To our knowledge, anti-TNFeinduced DM
has not been previously reported in a patient with
psoriasis.
Vasculitis, psoriaform eruptions, and a lupus-like
syndrome are the most common a-TNFeinduced
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reports, including our own.4 Five of the 8 prior cases
were patients with underlying rheumatoid arthritis;
one had Crohn disease, one had underlying
juvenile idiopathic arthritis, and one had seronega-
tive inflammatory arthritis.4 Four of the previous 8
cases were induced by adalimumab, 3 were induced
by etanercept, and 1 was induced by both
adalimumab and etanercept.4 In many of the
previous reports, direct causality was difficult to
establish due to the length of time between therapy
initiation and symptom development.4 In our case,
the DM symptoms began after 1 month of treatment,
making causality more likely.
a-TNF agents continue to be a safe and effective
treatment for various dermatologic and rheumato-
logic conditions. Due to the increasing popularity
of these agents, practitioners should be cognizant
of their potential to paradoxically induce autoim-
mune disease. The spectrum of presentations can
be widely varied and can exhibit symptomatic
overlap with other connective tissue disease.
Therefore, it is imperative to maintain a high
degree of clinical suspicion when prescribing these
medicines.
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Drug hypersensitivity syndrome in a patient
receiving vismodegib
To the Editor: Vismodegib (Erivedge) is a hedgehog
signaling pathway inhibitor that is FDA-approved for
the treatment of advanced basal cell carcinoma
(BCC).1 Common adverse effects include nausea,
vomiting, dysgeusia, decreased appetite, and weight
loss.1 Here we present a patient treated with vismo-
degib who developed drug hypersensitivity syn-
drome (DHS).
A 77-year-old woman presented with numerous
primary and recurrent BCCs on her face, trunk, and
extremities. Her past medical history was significant
for psoriasis that was treated with whole body
radiation decades earlier and currently controlled
with ustekinumab 45 mg subcutaneously every 3
months for the past 2 years. After much consider-
ation and numerous prior surgeries, she was started
on oral vismodegib 150 mg daily to treat more than
20 primary and recurrent BCCs (off-label indication).
Three weeks into treatment, nausea, vomiting, dys-
geusia, decreased appetite, and weight loss abruptly
developed; all are common adverse effects of
vismodegib. Additionally, she had chills, myalgias,
and extreme fatigue. The medication was discon-
tinued due to intolerability. Because there were rare
reports of treatment-emergent electrolyte distur-
bances in clinical trials of vismodegib,2 empirical
laboratory specimens drawn 2 days after discontinu-
ing the medication were remarkable for AST 143 U/L
(normal 15 to 41), ALT 200 U/L (normal 7 to 35),
alkaline phosphatase 345 U/L (normal 32 to 120),
and total bilirubin 4.4 mg/dL (normal 0.3 to 1.2).
White blood cell count was normal at 7.5 but with
eosinophilia of 17.9% (absolute eosinophils 1300/
L). Basic metabolic profile was normal. Due to the
mixed pattern of liver abnormalities, abdominal
ultrasoundwas performed andwas noncontributory.
Liver panel was improved 10 days after discontinu-
ing vismodegib and was completely normal after 1
month. By this time, her only complaint was a
residual ‘‘fuzzy tongue’’ sensation that resolved
over the next 3 months. A thyroid stimulating hor-
mone and free T4 level were normal 4 months later.3
Repeat laboratory evaluation after her next usteki-
numab injection, including white blood cell count of
7.4 with 0.9% eosinophils, was also normal.
